Home >> DC3

DC3: Epigenome and transcriptome in depth analysis of patient-derived model for CPs, mapping of possible alterations and effects of epi-drugs on the profiles – UM

DC3 – (UM) will analyse epigenetic and transcriptomic profiles of primary cells retrieved from individuals affected by CPs, as well as from the generated zebrafish models. A focus will be given to the Kabuki syndrome, in close collaboration with D. Genevieve, also a member of the ITN. Both active and inactive epigenetic marks will be analysed using CUT&RUN technology. The objective will be to determine which genes and active/inactive regulatory elements of the genome are perturbed in different subsets of lymphocytes and neurons and how this active/inactive balance is affecting their function. DC3 will determine the effects of the treatment with the epi-drugs on immune and neuronal cells. Specifically, DC3 will perform the transcriptomic and the epigenetic profile of both patient-derived and zebrafish T cells upon treatment with the selected epi-drugs to define the molecular basis of the cellular response to these treatments.

By using the site, you agree to our use of cookies. More info

This site uses cookies to provide the best browsing experience possible. By continuing to use this site without changing your cookie settings or by clicking on "Accept" you allow their use.